Navigation Links
Comprehensive Review of Cancer Immnunotherapies Published By CEL-SCI
Date:10/29/2007

VIENNA, Va., Oct. 29 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (Amex: CVM) announced today that it has published a very comprehensive review of cancer immunotherapies on its new website. The link is located in the top right hand corner of its home page at http://www.cel-sci.com .

Geert Kersten, Chief Executive Officer of CEL-SCI said, "Immunotherapy in the minds of many represents the future of cancer therapy. We have created an easy to navigate, interactive web based review that is designed to be helpful to doctors, patients as well as investors."

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product is Multikine(R). In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery. The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine as a neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.

The Company has operations in Vienna, Virginia and Baltimore, Maryland. CEL-SCI's other products, which are currently in pre-clinical stage, have shown protection against a number of diseases in animal tests and are being tested against diseases associated with bio-defense.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. A Comprehensive CD-ROM On HIV/AIDS Released By Center for HIV Information
2. ‘Comprehensive Sex Education’ Favored Against ‘Abstinence-Only’ Progams
3. Comprehensive Reforms to Move Toward Patient-Centered Care
4. Australia Proposes Comprehensive Plans to Protect Aboriginal Children from Sexual Abuse
5. UK Sports Clubs Failing to Run Comprehensive Health Checks on Professional Players
6. FDA may speed review of new drugs
7. Scientists review SARS
8. US Reviews Risks Of Tamiflu After 12 Children Die
9. Breast Cancer Examinations To Be Reviewed In Irish Hospitals
10. BioCryst’s Bird Flu Drug Enjoys Fast-Track Review By FD
11. A Sneak Preview of Human’s Susceptibility to Auto Immune Disease, Allergy, Asthm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , ... January 20, 2017 , ... ... products to enhance people’s everyday lives, recently attended the January ECRM Trade Show ... ATP Science is known for its large range of supplements that keep the ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes ... of Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have a ...
(Date:1/20/2017)... ... ... Angel”: a heartwarming and earnest tale of faith and believing in the path ... the creation of published author, Marjorie Lund-Fontaine, a former professional violinist, alumnus of The ... of her new book, Marjorie says, “‘The Angel’ was written as a fairytale, but ...
(Date:1/20/2017)... Farmville, NC (PRWEB) , ... January 20, 2017 ... ... the vPEP ® Oscillating Positive Expiratory Pressure (OPEP) device, was featured in ... article by Doug Pursley, MEd, RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive ...
(Date:1/20/2017)... ... ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of prayers that reminds ... published author, Gene Gaapf, a retired truck driver, and a long-time writer, whose published ... high school and have many different titles,” Gaapf mentions about his different works. “I ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 2017 This report on the opioid induced ... of the global market. Large number of chronic pain ... constipation is a major side effect of consumption of ... targeted therapy has been prescribed to treat opioid induced ... medicines, and growing awareness about the therapy are the ...
(Date:1/19/2017)... , Jan. 19, 2017  Stealth BioTherapeutics Inc. ( ... treat mitochondrial dysfunction, today announced new additions to its ... as Chief Medical Officer, and Daniel Geffken ... that Jim Carr , Pharm.D. has been promoted ... are pleased to welcome Doug and Daniel to our ...
(Date:1/19/2017)... -- According to a study conducted by Persistence Market ... a CAGR of 6.5% during the forecast period 2016-2024. According to ... be the leading market for cryotherapy globally during the forecast period  ... Highlights from the ... and adequate supply of gas in order to provide smoother maintenance ...
Breaking Medicine Technology: